Information Provided By:
Fly News Breaks for September 6, 2019
XLRN
Sep 6, 2019 | 12:36 EDT
H.C. Wainwright analyst Edward White maintained a Buy rating and $69 price target on Acceleron Pharma after sotatercept received orphan drug designation from the FDA for the treatment of patients with pulmonary arterial hypertension. In a research note to investors, White says Acceleron is evaluating sotatercept in PAH patients in the randomized, double blind, placebo-controlled PULSAR Phase 2 trial, which is assessing sotatercept plus standard of care versus placebo plus SoC in participants with PAH of WHO Group 1, functional class II-III. White says topline results for the PULSAR trial are expected in the first quarter of 2020, while the Phase 2 SPECTRA exploratory trial in adult PAH patients that receive SoC plus sotatercept for a 24 week treatment period followed by a 16 week follow up period is enrolling and is expected to have preliminary results in 2020.
News For XLRN From the Last 2 Days
There are no results for your query XLRN